Table 3.
Summary of risk factors considered by 11 European adult ALL study groups for risk stratification orientating the choice of an allogeneic HCT in first CHR in Ph− ALL (all studies including AYA patients), adapted from [54]. For MRD levels defining MRD POS status.
| Study Group | MRD | Genetics | WBC | Miscellaneous |
|---|---|---|---|---|
| RALL | + | KMT2A+, t(1;19) |
- | Age > 30 |
| GMALL | + | KMT2A+ | >30 (B) | Late CR, proB, early/mature-T |
| HOVON | + | adverse | >30 (B), >100 (T) | Late CR |
| PALG | + | KMT2A+ | >30 (B), >100 (T) | CNS+ |
| FALL | + | Abn11q, hypodiploid |
>100 | Late CR, D15 BM blasts > 25% |
| GIMEMA | + | adverse | >100 | Early/mature-T |
| UKALL | + | adverse | High counts | - |
| SVALL | + | KMT2A+, hypodiploidy |
- | EOI BM blasts > 5% |
| CELL | + | - | - | - |
| PETHEMA | + | - | - | - |
| GRAALL | + | - | - | - |
Complete list of adverse genetics/cytogenetics available in original study references. Abbreviations: WBC, white blood cells (×109/L); BM, bone marrow; CNS, central nervous system; D, day; EOI, end of induction; CELL, Czech Leukemia Study Group; FALL, Finnish ALL Study Group; GIMEMA, Gruppo Italiano Malattie Ematologiche dell’Adulto; GMALL, German Multicenter Study Group for Adult ALL; GRAALL, Group for Research on Adult ALL; HOVON, Hemato-Oncology Foundation for Adults in the Netherlands; PALG, Polish Adult Leukemia Group; PETHEMA, Programa Español de Tratamientos en Hematología; RALL, Russian ALL Study Group; SVALL, Swedish Adult ALL Study Group; UKALL, United Kingdom ALL Study Group.